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Abstract  
 
OBJECTIVE: Given the increasing use of oral antineoplastic agents in cancer management, patient adherence  
is critical to successful treatment outcomes. This article reviews the scope of the problem and issues of  
adherence to oral antineoplastic agents.   
 
DATA SOURCES: Research based and other articles, newsletters, and conference presentations. 
 
CONCLUSION: Suboptimal adherence to oral antineoplastic agents is a significant clinical problem that 
may result in disease or treatment complications, adjustment in treatment regimen, disease progression, 
and premature death.  
 
IMPLICATIONS FOR NURSING PRACTICE: Healthcare providers need to monitor and facilitate 
adherence by identifying barriers and implementing strategies to assure adherence, and therefore, improve 
clinical outcomes. 
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Recent progress in the treatment of cancer has seen an accelerated use of oral antineoplastic 
agents. At this time, nearly 50 oral antineoplastic agents are approved for use in the United States alone, 
with nearly half of all new agents in development being oral.1,2 This new treatment paradigm shifts 
delivery of intravenous chemotherapy from a safe, controlled process monitored on a regular basis by 
oncologists and oncology nurses in hospitals or outpatient clinics to patients’ homes  where the 
complexity of knowing dosing, side effects, and toxicities becomes the patient and family responsibility. 
The dosing regimens are often complex, and even for the most medically sophisticated patient and family, 
responsibilities for monitoring and taking medications, and then managing symptoms, side effects, and 
adverse events can be overwhelming.2 The problem is especially grave for cancer patients who often 
require long-term or lifelong therapy, because poor medication adherence leads to unnecessary disease 
progression, disease complications, reduced functional abilities, a lower quality of life, and premature 
death.3 In this article, the problem, scope, and issues involved with adherence to oral antineoplastic agents 
are discussed. 
The Definition of Adherence   
There is no “gold standard” definition of adherence. However, there is a vast literature examining 
medication adherence, most of which offer definitions.  
Conceptual Definition of the Health Status Outcome Adherence 
The World Health Organization defines adherence as the extent to which a person’s behavior corresponds 
with agreed recommendations from a health care professional.4 A commonly used definition is the extent 
to which a person’s behavior-taking medications, following a diet and/or exercising follows 
recommendations from a healthcare provider.5 A more precise definition of medication adherence was 
recently offered by the International Society for Pharmacoeconomics and Outcome Research (ISPOR), as 
“the degree or extent of conformity to the recommendations about day-to-day treatment by the provider 
with respect to the timing, dosage, and frequency.” ISPOR extends this definition by adding persistence, 
which they define as “the duration of time from the initiation of the medication to discontinuation of 
therapy”.6 Each of these conceptual definitions lay the foundation for measuring adherence. 
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Operational Definition of the Health Status Outcome Adherence 
Medication adherence is routinely operationalized in the literature as a percentage of how many of the 
prescribed pills a patient has taken (i.e., 80%, 90%, or 100%) compared to what they were prescribed. In 
many instances in the literature, a patient is considered to be adherent when they have taken 80% of a 
prescribed medication.7 Often, when self-report of medication adherence is used as the measure, a yes or 
no (dichotomous) question is asked of the patient.8,9 When Medication Event Monitoring System 
(MEMS [electronic pill boxes that alarm and measure cap openings]) are used, the number of bottle 
cap openings are compared to the number of expected bottle cap openings that are prescribed during a 
treatment period.10 When pharmacy claims data are used to examine adherence, a proportion of the days 
that the patient had the medication available is compared to the proportion of the days that the patient had 
the medication prescribed over the observation period and is calculated as the percentage of adherence.11 
When biologic measures, such as urine or serum assays are used, specific ranges of blood or urine levels 
are expected to be associated with adherence to a medication regimen.12,13 The operational definition of 
adherence is dependent upon which of these measures, or combination of these measures, is used to assess 
adherence. 
Definition of adherence used in research on oral agents. Three systematic reviews have been 
conducted on oral antineoplastic agents. One review of 12 studies used the most commonly cited 
definition of adherence in the literature, ‘the extent to which a person’s behavior coincides with medical 
or health advice’,14 a second review (n = 22) used the ISPOR definition,15 while the third (n = 6) 
concluded that no standard definition of adherence was used across studies and this made comparison of 
results between studies difficult.16 Of the 43 studies in the literature, only 24 reported a definition of 
adherence (See article on assessment and measurement elsewhere in this issue). Examples of general 
definitions were 90%-100% of pills taken and/or the extent to which a person’s behavior coincides with 
medical or health advice. Specific definitions included 100% adherence for taking mediation at correct 
date or time, or the prescribed number of doses taken based on pill count and MEMS, within 2-hours of 
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prescribed dosing interval and with the correct number on day of treatment.17 Definitions of adherence are 
more precise and measurable in the more recent oral antineoplastic agent studies. 
The definition to be used in this issue of Seminars in Oncology in Oncology Nursing is that 
offered by ISPOR and is the “the degree or extent of conformity to the recommendations about day-to-
day treatment by the provider with respect to the timing, dosage, and frequency” and “the duration of time 
from the initiation of the medication to discontinuation of therapy”. The ISPOR definition encompasses 
the complexity of dosing regimens for oral antineoplastic agents.  
Frameworks Used to Examine Medication Adherence 
Problems with medication adherence include patient factors, disease factors, and system factors. 
Patient factors can include age, education, income, cognition, attitude, beliefs, expectations, perception of 
illness, the environment, or health literacy. Influencing disease factors can include number of comorbid 
conditions, severity of disease, severity of outcome, and response to treatment. System factors may 
include the organizational structure of the healthcare system, the relationship with provider, and distance 
to health services.18 The Health Belief Model, often used to study adherence, focuses on the individual’s 
evaluation of his or her own health condition (disease severity and perceived vulnerability to the disease 
state), risks and benefits of adherence to the medication, and “cues to action” that prompt taking the 
medication.19 Piette and colleagues18,20 examined regimen complexity, sociodemographic characteristics 
such as living alone and distance from children, disease characteristics and comorbidities, and trust with 
clinicians that influence medication adherence. Dunbar-Jacob and colleagues21-23 examine the 
sociodemographic (age, education, marital status, ethnicity, income, and insurance), psychosocial 
(depression, personality traits, optimism, and emotion expressiveness), health status (smoking status, 
body mass index, physical activity, and cancer or heart disease), and procedural factors (pill type, changes 
in pills, and clinic site). Given and colleagues24  used a cognitive behavioral model in an educational 
approach to symptom management coupled with reminders to take medications in a trial on oral 
antineoplastic agent adherence. To a great extent, the literature on oral antineoplastic agent adherence 
does not include a framework. This has limited understanding of the factors that may influence adherence. 
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Factors That Affect Adherence 
A large body of empirical evidence exists on factors contributing to medication adherence in 
general, as investigators have tried to identify predictors of nonadherence to develop interventions. 
However, the relationship between these factors and adherence have been inconsistent; and most studies 
have found weak associations (< 0.15 r) with nonadherence.25,26 No simple explanation for nonadherence 
exists. Nonetheless, the following are the patient, disease, and system factors found in the literature 
associated with nonadherence (See Table 1).   
Patient Factors 
Sociodemographics. Age, race, education, and income level seem to influence adherence. 
However, the role of age in predicting adherence is unclear with some arguing elderly have routines 
which lead to better adherence,27 while others have found errors of omission and nonadherence.28,29 
Middle age adults are known to make more adherence errors than the elderly.27-29 In breast cancer patients 
taking long-term tamoxifen, younger women are more adherent.7,30,31 In some instances, males, non 
Caucasians, those who have less than a high  school education, and are low-income have been found to be 
less adherent.32-34 
Depression. In general, studies relate depression with lower adherence.35,36 In some instances, 
anxiety seems to contribute to nonadherence.37, In cancer patients, increased depressive symptoms are 
associated with nonadherence.31,33,38 The mechanism by which symptoms impact adherence remains 
unclear and likely complex, yet when identified could ultimately be a modifiable risk factor.39 Scientists 
theorize that increased levels of depression may decrease the capability to be adherent. 
 Beliefs about treatment and outcome expectation. There is some evidence that adherence 
correlates with a patient’s belief in the severity of the disease to be prevented or treated,23,40,41 thus one 
would expect all cancer patients to adhere. Patient perceptions about their illness strongly influenced 
adherence in cancer patients, consequently affecting the patients’ motivation, and ultimately, the ability of 
the oral antineoplastic agents to effectively manage the disease.14  For example, in breast cancer patients 
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taking Tamoxifen, the belief that nothing was to be gained by taking the oral antineoplastic agent was the 
predominant determinant of adherence.9,42 
Health literacy. Approximately 25% of the US population is illiterate.43 Even patients who can 
read and understand simple materials may be unable to comprehend more complicated written 
information about their disease and medications to treat it. Health literacy is the ability to read, 
understand, and act on health information. Poor skills lead to medications error, and impair the ability to 
remember and follow treatment recommendations and reduce effective interaction with providers.   
Social support environment. Family members, friends, and caregivers are an important 
component of the social environment and they can provide reminders to take the medication or administer 
the medication when necessary. Social support has been associated with good medication adherence.44 
Disease Factors 
Disease type. Literature on poor adherence to oral medications can be found for many types of 
diseases. This includes antihyperglycemics for diabetes (28.9%),45 lipid lowering drugs for coronary 
artery disease (8% to 40.6%),46,47 statins for acute coronary syndromes (20.0% to 40.1%),48,49 
antipsychotic drugs for psychosis (21.2%),50 protease inhibitor therapy for HIV (41.0%),51 and 
immunomodulatory drugs for multiple sclerosis (27.0%).52 As stated earlier, adherence for cancer patients 
ranged from 16% to 100% and these findings will be discussed further in the article on measurement 
elsewhere in this issue. 
Disease stage. Often, oral antineoplastic agents are prescribed for patients in later stages of 
disease as a last resort after other types of treatment have failed.24 However, gefitinib recently improved 
survival among metastatic lung cancer patients as a first drug line in a phase III trial.53 Clinicians have 
reported using erlotinib for first line treatment in a small subset of advanced unresectable lung cancer 
patients who have a particular gene mutation.54 
Side effects of disease or treatment. The frequency, severity, and type of side effects of the 
medications or the disease may also affect adherence. Studies of chronic disease indicate that patients 
decrease adherence as symptoms and side effects occur.9,35,55-58 Side effects from the disease and/or the 
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treatment of cancer may also affects adherence.9,33 Given and colleagues24 recently conducted an 
intervention study finding symptom management improved adherence.  It is probable that when patients 
perceive symptoms to be associated with oral agents, they are more likely to modulate adherence to self-
manage symptoms.  
Complexity of the dosing regimen. A large meta-analysis of 76 studies demonstrated that 
adherence is adversely proportional to medication-taking frequency.59 Decreasing the frequency of the 
dose is known to improve both symptom control and adherence.60  Oral agents are often administered on 
different dosing schedules and the complexity of the regimen may have an effect on adherence.9,61-63 As 
noted earlier in the Given24 study, as the complexity of the dosing regimen increased, adherence 
decreased. Examples of complex regimens include the 14 days on, 7 days off, medication cycle or the 7 
days on, 7 days off, medication cycle. 
Polypharmacy and drug interactions. One study on polypharmacy with oncology pharmacists 
identified 12 clinically significant potential drug-to-drug interactions with oral antineoplastic agents and 
commonly used medications.64 Drug-to-drug interactions can lead to adverse clinical outcomes, 
particularly in oncology, because of the narrow antineoplastic index of oral agents and a high risk of 
additional medications prescribed for age-related organ dysfunction.65,66 Not all drug—drug interactions 
can be predicted, and those that are predictable are not always avoidable. However, increased awareness 
of the potential for these interactions will allow healthcare providers to minimize the risk by choosing 
appropriate drugs and by monitoring for signs of interaction.66  
System Factors 
Relationship and communication with healthcare provider. Clinicians generally assume that 
patients are taking drugs as prescribed, and if a clinician discusses the topic with their patient, they 
believe patients when they say they are adherent.14 Specific clinician practices, continuity of care, and 
convenience of the office setting,67,68 and the relationship between the patient and the health care 
provider14,69 have had weak to moderate associations with adherence. When clinicians are aware of 
potential adherence problems, they have been unable to predict which patients may be nonadherent.70,71 A 
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systematic review of the research on communication between patients and healthcare providers about 
medications found that when physicians tended to dominate discussions,  patient adherence decreased.72,73 
Out-of-pocket costs. Out-of-pocket costs for medications have been found to be a risk factor for 
nonadherence.18,20 In oncology, large out-of-pocket costs of oral agents62,74,75 have influenced adherence.  
Although a person might believe that he is fully capable of following a prescribed treatment regimen, he 
may not adhere to therapy if he does not believe that his cost-benefit balance favors adherence.14 So, for 
cancer patients, if out-of-pocket costs are significant, adherence may be more difficult. Medications 
delivered orally may be more costly than those by infusion, as insurance is more likely to cover infusions 
that are given in a hospital or clinic as opposed to at home 
 In summary, there are many factors that may influence adherence. However, most studies have 
found weak associations. Clinicians need to be aware of factors that may influence adherence when 
developing strategies to reduce nonadherence. 
The Benefits and Disadvantages of Oral Antineoplastic Agents  
Several emerging trends in use of oral antineoplasticts are listed in Table 2. Despite difficulties 
with adherence, oral antineoplastic agents provide a potentially enhanced mode of cancer control by 
sustaining drug levels and prolonging continuous drug exposure to cancerous cells. The continual 
suppression of cancer cell growth prevents disease progression. Other advantages of oral antineoplastic 
agents include patient benefits, such as minimal disruption in work life, eliminating transportation issues, 
reducing the overall visits to the clinic or doctor’s office, and eliminating the need for intravenous access. 
Some patients prefer oral antineoplastic agents because they are perceived as less toxic and will choose 
them over I.V. agents when the two therapies are considered equally effective.76 However, other patients 
consider it a less “serious” form of therapy, and feel that I.V. therapy is needed for maximum benefit.  
One of the major drawbacks of oral antineoplastic agent is that there is less opportunity for healthcare 
professionals to interact with patients, assess disease response and toxicity, and to provide symptom 
management guidance or education to patients.  
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Antineoplastic Index for Oral Cancer Treatments.  
Molecularly targeted oral antineoplastic agents are highly selective for molecules that establish 
and maintain malignant cell expression, thus, the major reason for increased emphasis on adherence to 
oral cancer therapies. For example, imatinib and erlotinib, are different from traditional chemotherapy 
because they inhibit or turn off enzymes active in cancer progression. Success rates with imatinib are 
high, but to achieve—and maintain—these results, long-term administration is required in responsive 
patients.77  Pharmacokinetic literature suggests a narrow antineoplastic index  for oral cancer agents,78 
thus  increasing the importance of adherence. Oral antineoplastic agents may be used as the sole treatment 
regimen, as with capecitabine79 in combination with other oral agents, or with intravenous chemotherapy 
treatment. What is not known is what level of adherence is required to achieve an antineoplastic dose 
when using oral agents under each of these treatment approaches. For example, the antineoplastic benefit 
derived from agents with longer half-lives may be minimally compromised by missed doses.80,81 Some 
studies have included assessments of adherence to  limit this type of error.82 However, adherence in a 
clinical trial tends to be much higher than what is observed in clinical practice.15 Furthermore, rates of 
adherence with oral medication in clinical studies are likely to be inflated over what would be observed 
outside of a trial because of the careful selection of patients for recruitment and the intense attention that 
is paid to them once they are enrolled.14,71 In the community cancer  setting, adherence is thought to be 
more challenging.  
Safe Handling of Antineoplastic Agents 
Recent discussions have highlighted the need for safe handling of potentially hazardous drugs, 
such as the antineoplastics. The American Society of Clinical Oncology and Oncology Nursing Society 
have established chemotherapy administration safety standards for the clinical setting.83 These procedures 
need to be implemented in the home setting to assure the patient and family members are safe.  
Adherence, an Unrecognized Problem 
In general, a review of 50 years of research across diseases found an overall nonadherence rate of 
24.5%, with minimal difference found in adherence for medications taken for prevention or treatment.84 
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Furthermore, adherence has been directly linked to effectiveness of medical treatment.68 The most 
common reasons for nonadherence are: not filling a prescription, incorrect dosing, altering medication 
times, forgetting, or stopping before advised.85,86 Problems with adherence are thought to be unintentional 
and are attributed to the patient’s forgetfulness, difficulty with adapting to changes in the daily routine, or 
being asymptomatic.34 However, patients may choose not to fill a script if they believe it will be 
ineffective or if the cost is prohibitive or they have no means of reaching a pharmacy.87 Evidence 
demonstrates that adherence to treatment regimens that are documented to reduce mortality or the risk of 
other catastrophic outcomes (e.g., death) is poor.88,89  
Adherence to Oral Antineoplastic Agents 
In oncology, cancer patients are thought to be highly motivated by the gravity of their disease, 
with “too much to lose” by being nonadherent ,as the majority of these patients are often in the late stage 
of their disease when other therapy has failed.90 However, some  patients experience confusion due to the 
complexity of the regimen, or may simply forget to take their medication, self-modulate their doses, or 
not obtain a prescription.24  
Adherence Rates in Oral Antineoplastic Agents.  Systematic reviews of antineoplastic agent 
studies (n = 22) found adherence ranged between 16% and 100%.14-16 What is not clear in many of these 
studies is if under dosing or over dosing led to the nonadherence. Given and colleagues24,91 conducted an 
intervention trial (n = 119) finding adherence was 88% (n = 50 of 57) for patients with a 28 day 
medication cycle, 36% (n=9 of 25) for patients with a 14 days on, 7 days off medication cycle, and 33% 
(n = 3 of 9) with a 7 days on, 7 days off medication cycle (full adherence was defined as 78% of 
medication taken).The low adherence rate found in these studies may compromise the therapeutic index 
needed when administering oral antineoplastic agents. 
Over Adherence in Oral Antineoplastic Agent Studies. Over adherence is also a problem. Over 
adherence was found at a rate of 48% (n = 12 of 25) for patients with 14 days on, 7 days off medication 
cycle, and at a rate of 67% (n = 6 of 9) with 7 days on, 7 days off medication cycle.24,91 In a randomized 
control drug trial with adherence as a secondary endpoint, researchers found over adherence: days of 
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taking medications beyond the end of an expected cycle; taking extra doses in one day; and missing a day 
and compensating with a double dose the next day.92 The high rate of over adherence found may cause 
toxicity or lead to adverse events. 
Adherence Persistence Rates in Non-hormonal therapy. Studies of persistence, or the duration of 
time from the initiation to the discontinuation of therapy, among oral antineoplastic agents are rare. 
However, insights can be learned from the long-term studies of tamoxifen use in breast cancer patients. 
Adherence rates from long-term studies of  breast cancer patients prescribed tamoxifen  following the end 
of chemotherapy found that rates declined over time, 17% in year 1, 19% to 28% in year 2, 21% to 38% 
in year 3, and 50% by year 4 of treatment.7,11,30,31,42, Therefore, in a regimen that takes place over 
prolonged time, adherence declines drastically. 
Reasons for Nonadherence . Three of the studies on oral antineoplastics collected information on 
patient-reported reasons for nonadherence. These reasons included reports of  carelessness about taking 
medications (80%),93  forgetting to take medication (30% to 60%),91,93  purposely skipped doses (35%),94 
late dosing (26.7%),94 concerns over side effects (16.6%)94  and 20% not understanding  written materials 
about the prescription.94 One study also found the complexity of the regimen drastically reduced 
adherence.24 These studies provide a general understanding of reasons for nonadherence, and point out the 
need for patients to have reminders when taking oral antineoplastic agents.   
The Consequence of Nonadherence to Oral Antineoplastic Agents 
Suboptimal adherence to oral therapies can have multiple consequences. Poor adherence can 
severely impede the efficacy of oral regimens.61 Poor adherence can lead to compromised healthcare 
provider communication, side effects and/or adverse events due to toxicities, increased use of healthcare 
resources, and decreased survival.   
Poor Healthcare Provider Communication 
Suboptimal adherence can  compromise the patient-provider relationship, as misconceptions 
about the effects of a therapy may lead to a breakdown in communication and negatively affect a patient’s 
view of care.90 The disconnect between what dose the patient receives and the clinician’s assumption that 
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the patient is taking the dose as prescribed, may result in the clinician changing the dose or agent due to a 
belief that the patient is non-responsive to the treatment or having unexpected side effects.2,74  
Ineffective Antineoplastic Agents 
As stated previously, when less than a therapeutic dose of an antineoplastic agent is taken, severe 
consequences may occur. This includes complications due to treatment or disease with reduced functional 
abilities and a lower quality of life, and in some instances, unnecessary disease progression and premature 
death.3  
Side effects, adverse effects, and toxicities. Patients who over-adhere, especially those who take 
doses more frequently than prescribed, or at the wrong time of day, may experience greater levels of 
toxicities.15  Consequently, side effects and adverse events may be more likely in patients who are 
nonadherent. 
Poorer survival. In general, an association has been found between medication adherence and 
mortality.95  For example, participants in the Beta Blocker Heart Attack Trial who took 75% or less of 
prescribed medications were 2.5 times more likely to die than were those who were adherent to 
treatment.96,97 This may also be true with oral antineoplastic agents.  
Increased Use of Healthcare Resources.  
Nonadherence in a variety of patient populations has been associated with increased use of health 
care resources, including more physician visits, higher hospitalization rates, and longer stays.26,88  Lack of 
adherence to oral chemotherapy can contribute to variability in a drug’s antineoplastic agent effect if a 
clinician incorrectly attributes the patient’s worsening condition to an absence of drug activity and may 
lead to unnecessary testing and hospitalization.31 
Strategies to Improve Adherence 
Mixed results have been reported for interventions to improve medication adherence in general91 
Effective strategies are multidisciplinary and multimodal.98,99 However, a recent systematic review of 
interventions to enhance patient adherence to medications concluded current methods are complex, labor-
intensive, and not predictably effective, therefore, not able to be used in the clinical setting.100 Simple pill 
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reminders such as plastic pill boxes and calendars have demonstrated effectiveness in some types of 
medication adherence studies, however limited evidence is available when the complexity of the regimen 
with oral antineoplastic agents and further study is needed. These findings will be discussed in detail in 
the article on interventions, providing guidance for practitioners. 
The Multiple Challenges to Oral Antineoplastic Agent Adherence 
Multiple challenges to oral antineoplastic agent adherence exist in research and clinical practice. 
The limited available evidence suggests that adherence to oral agents is a significant clinical problem and 
may have a substantial impact on the antineoplastic agent success or failure of oral regimens for the 
prevention or treatment of malignancies. Patient adherence to antineoplastic regimens will be increasingly 
important to oncology as additional oral treatments are adopted for use in cancer care.15  
In research, there is no ‘gold’ standard definition for adherence, to allow for comparison across 
studies. Additionally, effective measurement methods of adherence are difficult to implement and track 
the medication regimen to identify if the patient is adherent or nonadherent. Measuring and studying 
adherence to oral antineoplastic agents is difficult because patients are aware of being observed and 
patients may adhere more than the average patient who is receiving the same therapy.15  Systematic 
assessment of adherence should be included in phase III trials, as well as off-study treatment with oral 
antineoplastic agents.  Future research needs to develop better methods for measurement and intervention. 
Poor adherence to medication is an ever-present and complex problem potentially contributing to 
substantial worsening of disease control,101,102 altering the outcome of treatment.14  
In clinical practice there is a need to better understand how patients’ determinants influence 
adherence and consequently develop interventions to assist patients to adhere to oral antineoplastic. 
Suboptimal adherence may adversely impact the efficacy and toxicity of oral therapeutic agents. Although 
the impact of nonadherence may differ between clinical care and research, and both are important.  
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